Michael Asbach
Physician Assistant · Amherst, NYNPI 1699030411
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $663,448 of the $961,873 with a category attached, or 69.0%. 55 manufacturers reported payments, led by Johnson & Johnson at 28.4% of the total. 2025 is the largest year on record at $296,343, 3.1 times the $97,011 reported in 2021. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,773 payments — averaging $346.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$273K
- Neurocrine Biosciences, Inc.$250K
- Axsome Therapeutics, Inc.$126K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$99K
- E.r. Squibb & Sons, L.L.C.$79K
- Teva Pharmaceuticals USA, Inc.$37K
- plus $98K from 49 others
What the payments were for
- Consulting fees$162,00317%
- Speaking & faculty fees$663,44869%
- Travel & lodging$86,2779%
- Food & beverage$49,4545%
- Education$6910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$961,873 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 55 | $436,125 |
| Austedo XrDeutetrabenazine | 13 | $170,851 |
| WakixPitolisant Hcl | 11 | $87,321 |
| FanaptIloperidone | 29 | $71,640 |
| NuedextaDextromethorphan Hbr/Quinidine | 38 | $66,891 |
| CaplytaLumateperone Tosylate | 40 | $66,582 |
| TrintellixVortioxetine Hydrobromide | 103 | $60,188 |
| VraylarCariprazine Hcl | 33 | $49,523 |
| RexultiBrexpiprazole | 26 | $37,655 |
| Lurasidone Hcl | 85 | $33,869 |
| AuvelityDextromethorphan Hbr/Bupropion | 28 | $28,809 |
| VivitrolNaltrexone Microspheres | 16 | $25,923 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $21,293 |
| Aripiprazole | 440 | $14,525 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 56 | $13,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $249,785 | $436,12555 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $37,497 | $170,85113 claims |
| Harmony Biosciences LLCWakix | $35 | $87,32111 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,376 | $71,64029 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $9,881 | $66,89138 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $99,461 | $66,58240 claims |
| AbbVieVraylar, Lexapro | $35,792 | $61,77145 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $914 | $60,188103 claims |
| Alkermes, Inc.Vivitrol, Lybalvi | $1,762 | $47,21629 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $28,364 | $37,65526 claims |
| Axsome Therapeutics, Inc.Auvelity | $125,603 | $28,80928 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $431 | $9,39319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Amherst
- Madeline SliszAmherst$101K
- Rachel AllenAmherst$54K
- Lauren JendraszekAmherst$40K
- Delaney FragaleAmherst$33K
- Henry YuBronx$1M
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.